REGN7075 Clinical Trials (2026): 5 Studies for Advanced Solid Tumors & Advanced/Metastatic Non-Small Cell Lung Cancer
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 REGN7075 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Advanced Solid Tumors & Advanced/Metastatic Non-Small Cell Lung Cancer) and 1,113 total planned enrollment. 3 REGN7075 clinical trials are actively recruiting at 25 U.S. sites across 16 states. Most recent activity: NCT07281768 (Jul 2030).
Where to Participate: All REGN7075 Trial Sites in the U.S. (25 sites across 16 states)
Every actively recruiting REGN7075trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Cancer Treatment Centers of America, Phoenix | Goodyear85338 | NCT07154290 | Map |
| CA | The City of Hope Orange County Lennar Foundation Cancer Center | Irvine92618 | NCT07154290 | Map |
| DC | Georgetown University | Washington D.C.20007 | NCT07154290 | Map |
| FL | University of Florida | Gainesville32611 | NCT07058012 | Map |
| FL | Mayo Clinic Jacksonville | Jacksonville32224 | NCT07154290 | Map |
| IL | Rush University Medical Center | Chicago60612 | NCT07154290 | Map |
| IL | University of Illinois Chicago | Chicago60612 | NCT07154290 | Map |
| IN | Franciscan Health | Munster46321 | NCT07154290 | Map |
| IA | University of Iowa - Holden Comprehensive Cancer Center | Iowa City52242 | NCT07058012 | Map |
| KS | University of Kansas Cancer Center | Kansas City66160 | NCT07058012 | Map |
| MD | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore21287 | NCT07281768 | Map |
| MD | University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore21201 | NCT07154290 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT07154290 | Map |
| MO | Missouri Baptist | St Louis63131 | NCT07058012 | Map |
| MO | Washington University School of Medicine | St Louis63110 | NCT07154290 | Map |
| NC | First Health of the Carolinas | Pinehurst28374 | NCT07058012 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT07058012 | Map |
| TN | Ballad Health Cancer Center - Kingsport | Kingsport37660 | NCT07058012 | Map |
| TN | University of Tennessee Medical Center | Knoxville37920 | NCT07154290 | Map |
| TN | Sarah Cannon Research Institute | Nashville37203 | NCT07154290 | Map |
| TX | University of Texas Medical Branch | Galveston77555 | NCT07154290 | Map |
| TX | The University of Texas MD Anderson Cancer Center | Houston77030 | NCT07154290 | Map |
| TX | Baylor Scott & White Health | Temple76508 | NCT07154290 | Map |
| VA | Bon Secours St. Francis Medical Center | Midlothian23114 | NCT07058012 | Map |
| VA | Virginia Commonwealth University - Massey | Richmond23298 | NCT07058012 | Map |
REGN7075 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P1/P2 | 1 | 1 | |
| P2 | 3 | 1 | 4 |
Recruiting REGN7075 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | P2 | Colorectal Cancer | 66 | Jul 2026 |
| NCT07154290 | REGN7075A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | P2 | Non Small Cell Lung Cancer | 300 | Mar 2026 |
| NCT07058012 | EMPIREA Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) | P2 | Colo-rectal Cancer | 79 | Apr 2026 |
REGN7075 clinical trials by indication
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07281768 | — | P2 | recruiting | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer |
Colo-rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07058012 | EMPIRE | P2 | recruiting | A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07154290 | REGN7075 | P2 | recruiting | A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) |
Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06465329 | NSCLC | P2 | active not recruiting | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04626635 | COMBINE-EGFR-1 | P1/P2 | active not recruiting | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers |
REGN7075 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| REGN7075 | NCT07154290 | P2 | recruiting | Non Small Cell Lung Cancer | 300 | — |
| NSCLC | NCT06465329 | P2 | active not recruiting | Non-Small Cell Lung Cancer | 120 | — |
| EMPIRE | NCT07058012 | P2 | recruiting | Colo-rectal Cancer | 79 | PMID 42345857 |
All REGN7075 trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer | P2 | recruiting | 66 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jul 2026 | |
| NCT07154290 | REGN7075 | A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | P2 | recruiting | 300 | Regeneron Pharmaceuticals | Mar 2026 |
| NCT06465329 | NSCLC | A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | P2 | active not recruiting | 120 | Regeneron Pharmaceuticals | Nov 2024 |
| NCT07058012 | EMPIRE | A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) | P2 | recruiting | 79 | NSABP Foundation Inc | Apr 2026 |
| NCT04626635 | COMBINE-EGFR-1 | A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | P1/P2 | active not recruiting | 548 | Regeneron Pharmaceuticals | Dec 2020 |
REGN7075 clinical trials: frequently asked questions
- How many REGN7075 clinical trials are there?
- 5 REGN7075 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are REGN7075 clinical trials recruiting in 2026?
- Yes — 3 REGN7075 trials are actively recruiting in 2026, with 25 U.S. sites across 16 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is REGN7075 being studied for?
- REGN7075 is being studied for Advanced Solid Tumors, Advanced/Metastatic Non-Small Cell Lung Cancer, Colo-rectal Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer. The trials are grouped by indication on this page.
- What phase is REGN7075 in?
- REGN7075 clinical trials span 4 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors REGN7075 clinical trials?
- The lead sponsor across the most REGN7075 trials is Regeneron Pharmaceuticals, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming REGN7075as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: